CDK
CDK (Cyclin-Dependent Kinase) inhibitors are compounds that block the activity of CDKs, a group of protein kinases that regulate the cell cycle, transcription, and other cellular processes. CDKs are activated by binding to cyclins, and their activity is crucial for the progression of cells through different phases of the cell cycle. Inhibiting CDKs can halt cell division, leading to cell cycle arrest and apoptosis, particularly in cancer cells where CDKs are often dysregulated. CDK inhibitors are widely used in cancer research and have therapeutic potential in treating various cancers. At CymitQuimica, we provide a comprehensive selection of high-quality CDK inhibitors to support your research in cell cycle control, cancer, and therapeutic development.
Found 500 products of "CDK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
CDK8-IN-12
CAS:<p>CDK8-IN-12: selective CDK8 inhibitor (Ki 14 nM), oral anticancer, blocks GSK-3α/β, PCK-θ, halts MV4-11 cell growth.</p>Formula:C21H20ClN3O2Purity:99.46% - 99.83%Color and Shape:SoildMolecular weight:381.86TMX-2138
CAS:<p>TMX-2138 is a CDKs PROTAC degrader, with IC50 values of 8.7 nM for CDK1/cyclinB, 10.9 nM for CDK2/cyclinA, 7.0 nM for CDK5/p25, and 25.7 nM for CDK9/cyclinT1. It enhances the ubiquitination and degradation of CDKs and is utilized for ovarian cancer research.</p>Formula:C40H43BrFN9O11SColor and Shape:SolidMolecular weight:956.791FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Color and Shape:LiquidLL-K8-22
<p>LL-K8-22: potent CDK8/cyclin C degrader; DC50 ~2.5μM; hinders STAT1 phosphorylation; curbs E2F/MYC cancer pathways; for TNBC study.</p>Formula:C37H43N5OColor and Shape:SolidMolecular weight:573.77Kinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Color and Shape:Odour SolidXY028-133
CAS:<p>XY028-133 is a PROTAC-based CDK4/6 degrader for the study of tumors.</p>Formula:C53H67N11O7SPurity:97.11%Color and Shape:SolidMolecular weight:1002.23CDK2-IN-19
<p>CDK2-IN-19 (Compound 32) is a selective, orally active inhibitor of CDK2 (K i: 0.18 nM) that exhibits anticancer activity in mice with OVCAR3 tumors [1].</p>Formula:C20H21FN6O4SPurity:98%Color and Shape:SolidMolecular weight:460.48CDK9-IN-27
<p>CDK9-IN-27 (Compound 6a), a CDK9 inhibitor with an IC50 of 0.424 μM, induces apoptosis and S-phase cell cycle arrest.</p>Formula:C23H18ClN5O3Purity:98%Color and Shape:SolidMolecular weight:447.87PROTAC CDK9 degrader 4
CAS:<p>PROTAC CDK9 degrader 4 is a CDK9 degrader that targets transcriptional regulation and has potential anticancer activity.</p>Formula:C43H56N10O5Color and Shape:SolidMolecular weight:792.97CDK4/6-IN-23
<p>CDK4/6-IN-23 (Compound 42) is a potent and selective inhibitor of CDK4/6, displaying an IC50 of 11 nM for CDK6. This compound significantly activates immune cells and enhances IL-3 production. In mice undergoing 5-FU chemotherapy, CDK4/6-IN-23 demonstrates dual bone marrow protection and immunomodulatory effects.</p>Formula:C32H34FN7O4Color and Shape:SolidMolecular weight:599.655CP-07
<p>CP-07 is a selective and effective PROTAC CDK9 degrader (DC50: 43 nM), demonstrating inhibition of 22RV1 cell proliferation (IC50: 62 nM) and colony formation</p>Formula:C45H48N6O8Purity:98%Color and Shape:SolidMolecular weight:800.9CDK1-IN-2
CAS:<p>CDK1-IN-2 (cdk1 inhibitor 2) is a CDK1 inhibitor with IC50 of 5.8 μM.</p>Formula:C17H11ClN2OPurity:98.53%Color and Shape:SoildMolecular weight:294.73Ribociclib hydrochloride
CAS:<p>Ribociclib hydrochloride is a highly specific CDK4/6 inhibitor (IC50: 10 nM and 39 nM, respectively).</p>Formula:C23H31ClN8OPurity:98%Color and Shape:SolidMolecular weight:471NCT02
CAS:<p>NCT02 degrades cyclin K, leading to CCNK and CDK12 degradation, potentially aiding metastatic CRC research.</p>Formula:C17H16N2O2SColor and Shape:SolidMolecular weight:312.39NU6102
CAS:<p>NU6102 is a CDK2 inhibitor with antitumor activity against CDK1/cyclinB, CDK1/CDK2, CDK4, DYRK1A , PDK1, and ROCKII, and it can be used to study rectal cancer.</p>Formula:C18H22N6O3SPurity:99.76%Color and Shape:SolidMolecular weight:402.47LDC4297
CAS:<p>LDC4297 (LDC044297) is a potent and selective CDK7 inhibitor.</p>Formula:C23H28N8OPurity:98.25%Color and Shape:SolidMolecular weight:432.52(E/Z)-Zotiraciclib hydrochloride
CAS:<p>(E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride is a potent inhibitor of CDK2, JAK2, and FLT3.</p>Formula:C23H25ClN4OColor and Shape:SolidMolecular weight:408.93GP-82996
CAS:<p>GP-82996 (CINK4) inhibits CDK4/6; IC50s: 1.5 μM (CDK4/D1), 5.6 μM (CDK6/D1), 25 μM (Cdk5/p35); triggers U2OS cancer cell apoptosis.</p>Formula:C27H32N6OPurity:99.94%Color and Shape:SolidMolecular weight:456.58CDK5-IN-3
CAS:<p>CDK5-IN-3 is a selective and potent CDK5 inhibitor that inhibits CDK5/p25 and CDK2/CycA, and can be used in the study of cancer.</p>Formula:C22H26N4OPurity:98.21%Color and Shape:SolidMolecular weight:362.47Palbociclib-d8
CAS:<p>Palbociclib-d8 (PD 0332991 D8) is the deuterated form of Palbociclib. Palbociclib is a CDK inhibitor that inhibits CDK4 and CDK6.</p>Formula:C24H21D8N7O2Purity:98%Color and Shape:SolidMolecular weight:455.58
